Navigation Links
Elevation Pharmaceuticals Strengthens Management Team with Appointment of Executives
Date:9/26/2011

eutical and biotech companies. Prior to PDL he was at Bristol-Myers Squibb, most recently as Vice President of Global Marketing where he received the "President's Award" for completing one of the most significant collaborations in the company's history. Prior to working for Bristol-Myers Squibb, Mr. Shah was at F. Hoffman-La Roche in international marketing and was global business leader for corporate alliances with Genentech and Idec. He holds an MA in Economics from the University of Akron and an MBA from the University of Oklahoma and serves on the Board of Directors at Acucela.

"Considering the positive Phase 2a trial results announced today and the draw-down of the $17 million tranche of its Series A financing, Elevation is poised to accelerate the development of its lead candidate and begin development of its pipeline," said Jaisim Shah. "I am very pleased to be joining the Company at this exciting stage, and I look forward to working with the rest of the management team to help realize Elevation's full potential."

Dr. Soni has more than 30 years of experience developing products in a range of industries, including 17 years in senior management leading the development, manufacture and registration of novel drug, device and combination medical products. At Elevation, Dr. Soni will be responsible for all device and drug development activities.  Prior to Elevation, he was Vice President of Product Research and Development at Alexza Pharmaceuticals where he led the development of a novel inhalable drug delivery system, the Staccato® inhaler, for systemic drug delivery via the deep lung. Five different drug candidates based on Staccato technology intended for the treatment of migraine, panic attack, breakthrough pain, insomnia and agitation are currently in various stages of clinical evaluation. Prior to Alexza, Dr. Soni was Vice President of Engineering at Cygnus where he led the development of the first commercial non-invasive, automatic,
'/>"/>

SOURCE Elevation Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Volcano Corporation Commends the Elevation of FFR to Level of Evidence A in New PCI Guidelines
2. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
3. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
4. Valeant Pharmaceuticals Intends to Raise Offer for Afexa Life Sciences Inc. to $0.85 per Share
5. Clermont Pharmaceuticals Reports Positive Phase III Results for Drug to Treat Glaucoma
6. Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
7. Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
8. Zacks Industry Outlook Highlights: Vertex Pharma, AstraZeneca, Abbott Labs, Allergan and Onyx Pharmaceuticals
9. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
10. Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
11. Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ("Juniper" ... three-month period ended March 31, 2015. First quarter financial highlights ... increase of 19% as compared to $7.0 million in ... increased 41% year-over-year, enabled by the return of normalized ... in the fourth quarter of 2014; , Service ...
(Date:5/6/2015)... , May 6, 2015 ... therapy with dolutegravir and rilpivirine   ... a Phase III clinical trial programme to evaluate ... rilpivirine (Edurant® [1] ) as maintenance therapy for ... comprises two replicate studies evaluating 48 week viral ...
(Date:5/6/2015)... Woodford Patient Capital Trust ... and the Bill & Melinda Gates Foundation to ... leading monoclonal antibody biopharmaceutical company, announced today that ... to complete a US$90 million Series B financing. ... Patient Capital Trust plc (LSE:WPCT,"Woodford") and Malin Corporation ...
Breaking Medicine Technology:Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10Kymab Secures US$90 Million Funding 2Kymab Secures US$90 Million Funding 3Kymab Secures US$90 Million Funding 4
(Date:5/6/2015)... Norcross, GA (PRWEB) May 06, 2015 ... has chosen Hexagon Geospatial technology to manage and distribute ... , Australia is one of the driest continents on ... supply through times of drought and erratic seasonal rainfalls ... water supply solutions. , Water NSW manages raw water ...
(Date:5/6/2015)... Mateo, Calif. (PRWEB) May 06, 2015 ... SafeMonk today announced a strategic partnership to help ... the cloud. The two industry-leading companies are teaming up ... platform. , “We’re thrilled to welcome SafeMonk ... to us that the people behind SafeMonk, the global ...
(Date:5/6/2015)... 2015 National Physical Fitness and Sports ... within the U.S. Department of Health and Human Services ... Fitness and Sports Month. It is dedicated to ... to health. Throughout the month of May, Americans ... fit. , The HHS details the benefits of regular ...
(Date:5/6/2015)... May 06, 2015 Most people in the ... nursing or other care after age 65. But less than ... for it or even talking about it, reports the May ... people risk two problems. One is losing control over the ... families," says Dr. David Grabowski, a professor of health care ...
(Date:5/6/2015)... Herndon, VA (PRWEB) May 06, 2015 ... its CIT GAP Funds has invested in e-Kare, Inc. ... speeds the assessment and monitoring of chronic wounds. , ... burn, and complex surgical wounds that affect over 6.5 ... in 2013 as a spin-off enterprise from the Children’s ...
Breaking Medicine News(10 mins):Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3Health News:Sookasa Grows Globally With SafeMonk Partnership 2Health News:Sookasa Grows Globally With SafeMonk Partnership 3Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 2Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 3Health News:Start Planning Now for Long-Term Care, from the May 2015 Harvard Health Letter 2Health News:CIT GAP Funds Invests in e-Kare 2Health News:CIT GAP Funds Invests in e-Kare 3
... 20 MCG Capital,Corporation (Nasdaq: MCGC ) today ... support the acquisition of Gould & Lamb, LLC by ... services company that is unique to,the workers, compensation industry. ... the workers, compensation industry,since 2001. Having completed in excess ...
... Hospitals are dangerous,places and the danger is even greater ... temps are relied on more than usual, and the ... McCaughey, Ph.D., Chairman of the Committee to Reduce Infection,Deaths, ... that hospital staff are eager to improve your safety ...
... DRAXIMAGE strong competitive position in ... Dec. 20 /PRNewswire-FirstCall/ - DRAXIMAGE, the,radiopharmaceutical division ... has appointed GE Healthcare, an industry leader ... DRAXIMAGE(R) Sestamibi in the United,States. DRAXIMAGE(R) Sestamibi ...
... 10 Law Offices of Howard G. Smith,announces ... be a lead plaintiff in,the securities class action ... common stock of Threshold Pharmaceuticals, Inc. ("Threshold,Pharmaceuticals" or ... 2005,and July 14, 2006 (the "Class Period"), including ...
... XCPT, LLC has entered into a,representation agreement ... dentists throughout the world. XCPT,s software is ... recognizing the importance of visual learning during,treatment planning. ... step of the,dental treatment process as the clinician ...
... Calif., Aug. 10 Mike Huckabee,will be the keynote ... at the Disneyland(R) Hotel in Anaheim, CA. The,event will ... "We are very honored to have a national ... who understands the importance of,Christian higher education as our ...
Cached Medicine News:Health News:MCG Capital Invests in Gould & Lamb 2Health News:How to Survive an Unexpected Trip to the Hospital During Christmas and New Years 2Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 2Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 3Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 4Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 5Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 6Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 7Health News:Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc. 2Health News:XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM) 2Health News:Presidential Candidate and Former Arkansas Governor Mike Huckabee to Be Keynote Speaker for Hope International University's 'Celebrate Hope' Dinner at Disneyland(R) Hotel 2
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
The perfect tool to prepare for in-service or licensing exams, for recertification, or for use as a clinical refresher....
... Med TruFlow™ Oxygen flowmeter with a Lexan®inner ... covering calibration and manufacturing defects. A wide ... most needs. Also available with all popular ... take-off and double unit configurations. Our extra ...
... TruFlow™ Oxygen flowmeter with a Lexan®inner calibrated ... calibration and manufacturing defects. A wide range ... needs. Also available with all popular inlet ... and double unit configurations. Our extra large ...
Medicine Products: